Basel Medical Group Ltd Ordinary Shares
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $5.7M
- Price
- $3.60
- % Change (Daily % change from the live per-ticker quote feed.)
- +9.76%
- Volume
- 122.8K
About
Basel Medical Group Ltd, an entity established in Singapore in 2023, is dedicated to delivering a comprehensive range of healthcare services. Its operations span multiple key areas, including specialist medical expertise, medical supplies and equipment, advanced medical technology solutions, and pharmaceutical products.
Quick stats
Shares outstanding1.6M
Computed float731.7K
Float / shares46.2%
Key info
SectorHealthcare
IndustryMedical - Care Facilities
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0002004489
Websitehttps://baselmedical.com
AI Summary
AI-generated1/7
criticalbearishoffering
Basel Medical Group Ltd (BMGL) Prices Registered Direct Offering
Basel Medical Group priced a registered direct offering of 6,000,000 units at US$1.33 per unit, raising US$7.98 million gross (about US$7.28 million net) with Cathay Securities as exclusive placement agent.
The dilution is extreme: the offering takes shares outstanding from 1,582,111 to 7,582,111, and each Common Warrant includes a zero-cash exercise option that can add another 6,000,000 shares with no additional proceeds to the company.
Company insiders and 5%+ holders signed 180-day lock-ups, and the company agreed not to pursue any additional financing for 180 days without placement agent consent.
The raise is heavily dilutive and warrant zero-cash mechanics signal investors paid essentially for stock, not for future exercise proceeds.
Red flags
- offering increases share count from ~1.58M to ~7.58M — roughly 380% dilution
- zero-cash exercise warrants add up to 6,000,000 more shares with no proceeds
- company explicitly does not expect additional funds from warrant exercises
- net proceeds ~91.5% of gross with unspecified use of proceeds
- tiny float relative to offering size raises overhang and volatility risk